ArticleCureus2024
Granulomatous Tubulointerstitial Nephritis as a Rare Cause of Allograft Failure: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although granulomatous interstitial nephritis (GIN) is a rare histological finding in kidney transplants, the joint occurrence of GIN and focal segmental glomerulosclerosis (FSGS) has not, to our knowledge, been reported in the literature. We report a case of GIN and de novo FSGS in kidney transplant recipients leading to allograft failure. A 69-year-old male with a history of end-stage renal disease (ESRD) of unknown etiology, as well as liver failure from hepatitis B and C co-infection, initially had a living unrelated kidney transplant (LURT) in 2007 and subsequently received both liver and kidney transplants (SLKTs) in 2017. His second post-transplant course in 2017 was complicated by antibody-mediated rejection, recurrent urinary tract infections, and an episode of cell-mediated rejection, which was treated with both corticosteroids and thyroglobulin. In 2023, his serum creatinine remained stable, ranging from 2.2 to 2.9 mg/dL, with maintenance immunosuppression of mycophenolate mofetil (750 mg twice a day), tacrolimus (4 mg twice a day; target of 5-7 ng/mL), and prednisone (5 mg daily). In February 2024, his serum creatinine increased to 4.3 mg/dL, with nephrotic-range proteinuria (urine protein-to-creatinine ratio of 6000 mg/g) and urinalysis showing pyuria (white blood cell count of 49), but no hematuria. All infectious work-ups, including urine culture, blood culture, QuantiFERON-TB Gold, and sputum
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.